phase 1 clinical trial | sciencenewsnet.in

Breaking News

DECam Confirms that Early-Universe Quasar Neighborhoods are Indeed Cluttered

DECam confirma que los vecindarios de los cuásares del Universo primitivo están realmente abarrotados

Drilling Down to the Details in Cancer Research

UWF alumni, community advocates Stephen and Mona Wright gift $500,000 to establish new institute

20-Week Ultrasound in Pregnancy is a Key Driver of Disparities in Prenatal Diagnosis of Congenital Heart Defects

Food Images Trigger Abnormally Low Reward Responses in Brains of People with Alcohol Use Disorder, Novel MRI Study Suggests

Sensiva Health names Ben Williamson as Chief Executive Officer

Inflation Reduction Act Funding to Help GCOOS Enhance Ocean Observations in Support of Coastal Communities, Climate Resilience and the Gulf’s Blue Economy

Menopause and midnight mayhem: 50% of women aged 45-64 report disrupted sleep

‘Litigant Shopping’ For Supreme Court Cases Can Backfire

23 Sep, 2024

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

September 23, 2024 sarah JonasAnnouncement

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.